{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-076153","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.356020+00:00","generated_at":"2026-05-17T15:26:26.291815+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TELA Bio Q2 2025 revenue $20.2M (+26% YoY); net loss narrows to $9.9M; reaffirms FY2025 guidance $85M-$88M","bullets":["Revenue $20.2M (+26% YoY); OviTex PRS product revenue up 53% YoY.","Net loss $9.9M vs $12.6M in prior-year quarter; operating loss $9.1M improved from $11.6M.","Gross margin improved to 69.8% vs 68.8% due to lower excess/obsolete inventory charge.","Appointed Jeffrey Blizard as President effective June 2025 to strengthen commercial leadership.","Reaffirmed FY2025 revenue guidance of $85M-$88M (23-27% YoY growth); cash $35.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-076153","json":"https://secwatch.observer/filing/0001104659-25-076153.json","markdown":"https://secwatch.observer/filing/0001104659-25-076153.md","text":"https://secwatch.observer/filing/0001104659-25-076153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465925076153/0001104659-25-076153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465925076153/tm2522957d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:26:26.291815+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}